Medicine Recommendations

Pagets Disease

Type 2 diabetes

Acute Gout (as per LSCMMG Guidelines)

Progestogenic opposition of oestrogen HRT in women with an intact uterus

Primary prevention of osteoporotic fragility fractures in postmenopausal women (NICE TA160)

NICE TA160 - Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended) 

Secondary prevention of osteoporotic fragility fractures in postmenopausal women (NICE TA161)

NICE TA161  Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended)

Moderate to severe symptoms of uterine fibroids (NICE TA832)

NICE TA832 - Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids

Osteoporosis (NICE TA464)

NICE TA464 - Bisphosphonates for treating osteoporosis 

Severe osteoporosis (NICE TA791)

NICE TA791 - Romosozumab for treating severe osteoporosis

Treating symptomatic anaemia in chronic kidney disease - NICE TA807

NICE TA807 - Roxadustat for treating symptomatic anaemia in chronic kidney disease

Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications; or in addition to other medicinal products for the treatment of diabetes.

NICE NG28 - Type 2 diabetes in adults: management

Managing overweight and obesity (NICE TA875)

NICE TA 875 - Semaglutide for managing overweight and obesity

For the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise.

Type 2 diabetes

Treating growth disturbance in children and young people aged 3 years and over (NICE TA863)

NICE TA863 - Somatrogon for treating growth disturbance in children and young people aged 3 years and over

Adult growth hormone deficiency (NICE TA64) & Growth failure in children (NICE TA188)

Sotagliflozin with insulin for treating type 1 diabetes (TA 622)

Treatment of severe osteoporosis

- in postmenopausal women;

- in adult men

at high risk of fracture, for whom treatment with other medicinal products approved for the treatment of osteoporosis is not possible due to, for example, contraindications or intolerance. In postmenopausal women, strontium ranelate reduces the risk of vertebral and hip fractures.

The decision to prescribe strontium ranelate should be based on an assessment of the individual patient's overall risks

MHRA Drug Safety Update - Strontium ranelate: cardiovascular risk—restricted indication and new monitoring requirements (March 2014)

For treating premenopausal women at high risk of breast cancer unless they have a past history or may be at increased risk of thromboembolic disease or endometrial cancer.

Secondary prevention of osteoporotic fragility fractures in postmenopausal women (NICE TA161)

NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women